drugset / Trial / NCT03445897

Miltefosine Plus IL Pentamidine for Bolivian CL

NCT03445897

Phase 2 Completed 50 enrolled Jonathan Berman
NaSingle-groupOpen-labelTreatment

Summary

Bolivian cutaneous leishmaniasis due to Leishmania braziliensis was treated with the combination of miltefosine (150 mg/day for 28 days) plus intralesional pentamidine (120 ug/mm2 lesion area on days 1, 3, and 5).

Timeline

Start
2016-01-31
Primary completion
2018-01-31
Completion
2018-02-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Miltefosine Small molecule 150 mg
Subject Pentamidine Unknown 120 unknown Other